Sutro Biopharma Inc banner

Sutro Biopharma Inc
NASDAQ:STRO

Watchlist Manager
Sutro Biopharma Inc Logo
Sutro Biopharma Inc
NASDAQ:STRO
Watchlist
Price: 26.76 USD -1.07%
Market Cap: $439.7m

During the last 3 months Sutro Biopharma Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 136% over this period (open performance analysis).

The last transaction was made on Oct 15, 2025 by Matsui Connie , who bought 40k USD worth of STRO shares.

Last Transactions:
Matsui Connie
$+4k
Chow Gregory K.
$+1.6k
Chung Jane
$+1k
Gerber Hans-Peter
$+1.4k
Pauling David
$+999
Vasquez Nicki
$-6.1k
Shtylla Brunilda
$-7.3k
Shtylla Brunilda
$-5.3k
Newell William J
$+7.8k
Vasquez Nicki
$-7.3k
Hallam Trevor
$-5.7k
Hallam Trevor
$-5.3k
Hallam Trevor
$-4.1k
Hallam Trevor
$-25.1k
Hallam Trevor
$-1k
Freund John Gordon
$-480k
Freund John Gordon
$-500k
Hallam Trevor
$-886.4
Freund John Gordon
$-436k
Hallam Trevor
$-789.9
Hallam Trevor
$-785.8
Hallam Trevor
$-980.3
Fitzpatrick Linda A
$+2.5k
Newell William J
$+50k
Molina Arturo Md
$+5k
Hallam Trevor
$-913.2
Hallam Trevor
$-950.1
Hallam Trevor
$-1k
Hallam Trevor
$-1k
Hallam Trevor
$-1.1k
Hallam Trevor
$-1k
Hallam Trevor
$-977.6
View All Transactions

During the last 3 months Sutro Biopharma Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 136% over this period (open performance analysis).

The last transaction was made on Oct 15, 2025 by Matsui Connie , who bought 40k USD worth of STRO shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
5
9k USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Sutro Biopharma Inc
Insider Trading Chart

Sutro Biopharma Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Sutro Biopharma Inc
Last Insider Transactions

Global
Insiders Monitor

Sutro Biopharma Inc
Glance View

Market Cap
439.7m USD
Industry
Biotechnology

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.

STRO Intrinsic Value
16.35 USD
Overvaluation 39%
Intrinsic Value
Price $26.76

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett